Peptide Initiative
Back to Pemvidutide

Clinical trials

Every registered trial of Pemvidutide

15 studies.

Plain-Language Summary

Plain-language reading of the public trial registries.

In short

  • Very little human research on Pemvidutide has been registered.
  • 15 registered studies in total.
  • None are currently enrolling — this research has already happened.

What kind of research

  • 15 studies actually gave the peptide to volunteers and measured what happened. This is the kind of study that can show whether something works.
  • About 1,315 people took part in those.

A registered trial is a plan, not a result. Registration means a study was declared in advance; it says nothing about whether the peptide worked, and a trial can be registered and then abandoned.

Filter

Showing 15 of 15 trials for Pemvidutide.

  • NCT07009860 Phase 2Active Not Recruiting121 enrolled2025

    RESTORE TRIAL: Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

    Altimmune, Inc.

    Alcohol-associated Liver Disease

  • NCT06987513 Phase 2Completed100 enrolled2025

    RECLAIM STUDY: Phase 2 Study of the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight

    Altimmune, Inc.

    Alcohol Use Disorder (AUD)

  • NCT05989711 Phase 2Completed212 enrolled2023

    IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)

    Altimmune, Inc.

    Non-Alcoholic Steatohepatitis (NASH)

  • NCT05295875 Phase 2Completed391 enrolled2022

    Efficacy and Safety of ALT-801 in the Treatment of Obesity

    Altimmune, Inc.

    Obesity/Overweight

  • NCT05292911 Phase 1Completed64 enrolled2022

    Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)

    Altimmune, Inc.

    Non-Alcoholic Fatty Liver Disease

  • NCT05134662 Phase 1Completed55 enrolled2022

    ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)

    Altimmune, Inc.

    Type 2 Diabetes

  • NCT05006885 Phase 1Completed95 enrolled2021

    ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)

    Altimmune, Inc.

    Non-Alcoholic Fatty Liver Disease

  • NCT04972396 Phase 1Completed40 enrolled2021

    Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

    Altimmune, Inc.

    NASH - Nonalcoholic Steatohepatitis

  • NCT04561245 Phase 1Completed100 enrolled2020

    ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability

    Altimmune, Inc.

    Obesity · Nonalcoholic Steatohepatitis

  • NCT01670994 Phase 1/2Terminated6 enrolled2012

    QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple Myeloma

    Altor BioScience

    Relapsed or Refractory Multiple Myeloma

  • NCT01625260 Phase 1/2Terminated12 enrolled2012

    A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

    Altor BioScience

    Non-muscle Invasive Bladder Cancer

  • NCT01478074 Phase 1Withdrawn2011

    ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

    Altor BioScience

    Acute Myeloid Leukemia

  • NCT01326871 Phase 1/2Completed68 enrolled2011

    A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer

    Altor BioScience

    Transitional Cell Carcinoma of Bladder · Urethra Cancer · Ureter Cancer · Malignant Tumor of Renal Pelvis

  • NCT01029873 Phase 1/2Completed25 enrolled2010

    QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma

    Altor BioScience

    Metastatic Melanoma

  • NCT00496860 Phase 1Completed26 enrolled2007

    Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

    Altor BioScience

    Progressive Metastatic Malignancies

Sources: ClinicalTrials.gov, the EU Clinical Trials Information System and ISRCTN, deduplicated so a study registered in more than one registry is counted once. A study is listed when Pemvidutide is named as an intervention. A registered trial is a plan, not a result — registration says nothing about whether the peptide worked.